RECRUITING

Dexamethasone Use in Pediatric Rhabdomyolysis Patients in Addition to Standard Protocols

Description

There is a significant unmet need for optimized treatment in rhabdomyolysis. There are few prospective interventional studies on treatment for rhabdomyolysis, a condition which affects diverse and underrepresented populations at a higher rate. While steroids are often used off-label, a systematic study has not yet been initiated, and steroids have not been yet considered in as a consideration to standard care guidelines. The hypothesis is that patients who receive dexamethasone in addition to standard care versus placebo and standard care will have improvement in pain, length of hospital stay, and decrease in kidney complications.

Conditions

Study Overview

Study Details

Study overview

There is a significant unmet need for optimized treatment in rhabdomyolysis. There are few prospective interventional studies on treatment for rhabdomyolysis, a condition which affects diverse and underrepresented populations at a higher rate. While steroids are often used off-label, a systematic study has not yet been initiated, and steroids have not been yet considered in as a consideration to standard care guidelines. The hypothesis is that patients who receive dexamethasone in addition to standard care versus placebo and standard care will have improvement in pain, length of hospital stay, and decrease in kidney complications.

A Clinical Trial to Assess Whether Dexamethasone Addition to Standard Protocols for Non-Traumatic Rhabdomyolysis of Unknown or Genetic Etiologies Improves Patient Outcomes

Dexamethasone Use in Pediatric Rhabdomyolysis Patients in Addition to Standard Protocols

Condition
Rhabdomyolysis
Intervention / Treatment

-

Contacts and Locations

Washington DC

Childrens National, Washington DC, District of Columbia, United States, 20010

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Already taking systemic steroids.
  • * Inability to comply with study instructions.
  • * Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
  • * Pregnant women.
  • * Below gestational age of 40 weeks
  • * Allergy to fluconazole, clotrimazole or nystatin.
  • * Cannot tolerate PO medications

Ages Eligible for Study

6 Months to 25 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Children's National Research Institute,

Natasha Shur, MD, PRINCIPAL_INVESTIGATOR, Children's National Research Institute

Study Record Dates

2026-12-31